Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
214.05B
Market cap214.05B
Price-Earnings ratio
11.33
Price-Earnings ratio11.33
Dividend yield
2.55%
Dividend yield2.55%
Average volume
12.81M
Average volume12.81M
High today
$48.78
High today$48.78
Low today
$47.89
Low today$47.89
Open price
$48.54
Open price$48.54
Volume
3.10M
Volume3.10M
52 Week high
$71.80
52 Week high$71.80
52 Week low
$35.12
52 Week low$35.12

NVO News

CNBC 7h
Medicare will start covering obesity drugs for the first time. Here's what patients should know

Key Points Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary prog...

Medicare will start covering obesity drugs for the first time. Here's what patients should know
TipRanks 19h
Novo Nordisk Accelerates Share Buybacks Under DKK 15 Billion Programme - TipRanks

...

Novo Nordisk Accelerates Share Buybacks Under DKK 15 Billion Programme - TipRanks
Nasdaq 1d
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

Novo Nordisk NVO and Viking Therapeutics VKTX are both riding on the powerful growth trend in obesity care, a market expected to expand significantly as demand...

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

Analyst ratings

54%

of 37 ratings
Buy
37.8%
Hold
54.1%
Sell
8.1%

More NVO News

Nasdaq 1d
NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.78, changing hands for $48.07/sha...

NVO Crosses Above Average Analyst Target
Simply Wall St 2d
Novo Nordisk Stock In Focus As Medicare Opens A New Wegovy Market

The Medicare Bridge program is set to open the door for millions of seniors to access obesity drugs such as Wegovy from Novo Nordisk and Zepbound from Eli Lilly...

Novo Nordisk Stock In Focus As Medicare Opens A New Wegovy Market
CNBC 2d
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

Key Points Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly c...

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Nasdaq 4d
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Key Points Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative. Novo’s steady insulin cash flows and n...

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?
TipRanks 5d
Novo Nordisk Tests Cagrilintide in Patients Who Cannot Tolerate GLP-1 Weight-Loss Drugs

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more...

Nasdaq 5d
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Key Points "The field is getting more crowded -- but Lilly is widening its lead,” said RBC analyst Trung Huynh. Until Novo Nordisk gets back to positive growt...

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
The Motley Fool 5d
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch

Investors looking to capitalize on the rapidly growing artificial intelligence (AI) industry tend to turn toward leading tech corporations. That's understandabl...

The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.